Biomedical Engineering Reference
In-Depth Information
Bruce L (2003) Generic pharmaceutical cases: a review of 2002's cases and 'long arm' relief—the
current position. Int J Med Market 3(3):199-203
Bulow J (2004) The gaming of pharmaceutical patents. In: Jaffe A, Lerner J, Stern S (eds)
Innovation policy and the economy, vol 4. MIT, Cambridge, MA, pp 145-187
Burdon M, Sloper K (2003) The art of using secondary patents to improve protection. Int J Med
Market 3(3):226-238
Caves RE, Whinston MD, Hurwitz MA (1991) Patent expiration, entry, and competition in the
U.S. pharmaceutical industry. Brookings Pap Econ Act 1991:1-66
Chandon P (2004) Innovative marketing strategies after patent expiry: the case of GSK's antibiotic
Clamoxyl in France. Int J Med Market 4(1):65-73
Ching AT (2010) Consumer learning and heterogeneity: dynamics of demand for prescription
drugs after patent expiration. Int J Ind Organ 28(6):619-638
Chong CR, Sullivan DJ Jr (2007) New uses for old drugs. Nature 448(9):645-646
Cockburn IM (2007) Is the pharmaceutical industry in a productivity crisis? In: Jaffe A, Lerner J,
Stern S (eds) Innovation policy and the economy, vol 7. MIT, Cambridge, MA, pp 1-32
Cockburn IM, MacGarvie MJ (2011) Entry and patenting in the software industry. Manag Sci
57(5):915-933
Conley JG, Wong E, Walcott RC (2006) “AstraZeneca, Prilosec, and Nexium: marketing chal-
lenges in the launch of a second-generation drug,” Kellogg School of Management case study,
KEL336. Kellogg School of Management, Evanston, IL
Danzon P, Furukawa MF (2008) International prices and availability of pharmaceuticals in 2005.
Health Aff 27(1):221-233
DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug
development costs. J Health Econ 22(2):151-185
Dubey R, Dubey J (2009) Pharmaceutical product differentiation: a strategy for strengthening
product pipeline and life cycle management. J Med Market 9(2):104-118
Ellison SF, Cockburn I, Griliches Z, Hausman J (1997) Characteristics of demand for pharmaceuti-
cal products: an examination of four cephalosporins. Rand J Econ 28(3):426-446
Ellison G, Ellison SF (2011) Strategic entry deterrence and the behavior of pharmaceutical incum-
bents prior to patent expiration. Am Econ J Microecon 3(1):1-36
Engelberg AB, Kesselheim AS, Avorn J (2009) Balancing innovation, access and profi ts: market
exclusivity for biologics. N Engl J Med 361(20):1917-1919
Evans DS, Salinger MA (2007) Curing sinus headaches and tying law: an empirical analysis of
bundling decongestants and pain relievers. In: Choi JP (ed) Recent developments in antitrust:
theory and evidence. MIT, Cambridge, IL
FDA (1999) “Guidance for industry: qualifying for pediatric exclusivity under Section 505A of the
Federal Food, Drug, and Cosmetic Act,”
http://www.fda.gov/downloads/Drugs/
Fleming E, Ma P (2002) Drug life-cycle technologies. Nat Rev Drug Discov 1(10):751-752
Forden S (2011) Pay for delay drug deals should be halted, FTC tells court.
Business Week
6 June
Frank RG (2007a) Regulation of follow-on biologics. N Engl J Med 357(9):841-843
Frank RG (2007b) The ongoing regulation of generic drugs. N Engl J Med 357(20):1993-1996
Frank RG, Salkever DS (1992) Pricing, patent loss and the market for pharmaceuticals. South
Econ J 59(2):165-179
Frank RG, Salkever DS (1997) Generic entry and the pricing of pharmaceuticals. J Econ Manag
Strat 6(1):75-90
Ganther JM, Kreling DH (2000) Consumer perception of risk and required cost savings for generic
prescription drugs. J Am Pharm Assoc 40(3):378-383
Ganuza J-J, Llobet G, Domínguez B (2009) R&D in the pharmaceutical industry: a world of small
innovations. Manag Sci 55(4):539-551
Gonzalez J, Sismeiro C, Dutta S, Stern P (2008) Can branded drugs benefi t from generic entry?
The role of detailing and price in switching to non-bioequivalent molecules. Int J Res Market
25(4):247-260
Search WWH ::
Custom Search